Lv1
50 积分 2024-09-05 加入
Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study
7小时前
已完结
Epstein-Barr Virus Antibodies to Differentiate Multiple Sclerosis From Other Neuroinflammatory Diseases
1个月前
已完结
Rates and Predictors of Serious Infections in MS and NMOSD Patients treated with Anti-CD20 Therapy (P7-3.008)
3个月前
已完结
Analysis of infection rates in neuromyelitis optica spectrum disorder: Comparing satralizumab treatment in SAkuraMoon, post-marketing, and US-based health claims data
3个月前
已完结
Peripheral immune profiling highlights a dynamic role of low-density granulocytes in myasthenia gravis
3个月前
已完结
Involvement of trained immunity during autoimmune responses
3个月前
已完结
Analysis of infection rates in neuromyelitis optica spectrum disorder: Comparing satralizumab treatment in SAkuraMoon, post-marketing, and US-based health claims data
3个月前
已完结
Clinical outcome and peripheral immune profile of myasthenic crisis with omicron infections: A prospective cohort study
3个月前
已完结
Immunoglobulin Kinetics and Infection Risk after Long-Term Inebilizumab Treatment for NMOSD
4个月前
已完结
Immunoglobulin kinetics and infection risk after long-term inebilizumab treatment for NMOSD
4个月前
已关闭
皖公网安备34019202002308
